Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2011

01-08-2011 | Original Paper

Gene expression in oligodendroglial tumors

Authors: Elisabeth J. Shaw, Brian Haylock, David Husband, Daniel du Plessis, D. Ross Sibson, Peter C. Warnke, Carol Walker

Published in: Cellular Oncology | Issue 4/2011

Login to get access

Abstract

Background

Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity.

Methods

Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy [26 serial stereotactic biopsy, 2 resection]. Expression of differentially expressed genes was validated by real-time PCR.

Results

Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status. 176 genes were differentially expressed, 164 being associated with 1p/19q loss (86% not on 1p or 19q). 94 genes differed between responders and non-responders to chemotherapy; 12 were not associated with 1p/19q loss. Significant differential expression was confirmed in 11/13 selected genes. Novel genes associated with response to therapy included SSBP2, GFRA1, FAP and RASD1. IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss.

Conclusion

Gene expression profiling using serial stereotactic biopsies indicated greater homogeneity within tumors than between tumors. Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
Appendix
Available only for authorised users
Glossary
WHO
World Health Organization
OII
oligodendroglioma grade II
OIII
oligodendroglioma grade III
OAII
oligoastrocytoma grade II
OAIII
oligoastrocytoma grade III
PCV
procarbazine, lomustine (CCNU), and vincristine
CR
complete response
PR
partial response
MR
minor response
PD
progressive disease
SD
stable disease
HPRT
hypoxanthyl-phosphoribosyl transferase
aRNA
antisense RNA
PCA
principle component analysis
SAM
significance analysis of microarrays
FDR
false discovery rate
ECACC
European Collection of Cell Cultures
Literature
1.
N. Ariga, E. Sato, N. Ohuchi, H. Nagura, H. Ohtani, Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer. 95, 67–72 (2001)PubMedCrossRef
2.
J.G. Cairncross, K. Ueki, M.C. Zlatescu, D.K. Lisle, D.M. Finkelstein, R.R. Hammond, J.S. Silver, P.C. Stark, D.R. Macdonald, Y. Ino, D.A. Ramsay, D.N. Louis, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473–1479 (1998)PubMedCrossRef
3.
H.Y. Cheng, H. Dziema, J. Papp, D.P. Mathur, M. Koletar, M.R. Ralph, J.M. Penninger, K. Obrietan, The molecular gatekeeper Dexras1 sculpts the photic responsiveness of the mammalian circadian clock. J. Neurosci. 26, 12984–12995 (2006)PubMedCrossRef
4.
S.J. Cleator, T.J. Powles, T. Dexter, L. Fulford, A. Mackay, I.E. Smith, H. Valgeirsson, A. Ashworth, M. Dowsett, The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 8, R32 (2006)PubMedCrossRef
5.
S. Draghici, P. Khatri, P. Bhavsar, A. Shah, S.A. Krawetz, M.A. Tainsky, Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res. 31, 3775–3781 (2003)PubMedCrossRef
6.
F. Ducray, A. Idbaih, A. de Reynies, I. Bieche, J. Thillet, K. Mokhtari, S. Lair, Y. Marie, S. Paris, M. Vidaud, K. Hoang-Xuan, O. Delattre, J.Y. Delattre, M. Sanson, Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol. Cancer. 7, 41 (2008)PubMedCrossRef
7.
P.J. French, S.M. Swagemakers, J.H. Nagel, M.C. Kouwenhoven, E. Brouwer, P. van der Spek, T.M. Luider, J.M. Kros, M.J. van den Bent, P.A. Sillevis Smitt, Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 65, 11335–11344 (2005)PubMedCrossRef
8.
E.M. Grasbon-Frodl, F.W. Kreth, M. Ruiter, O. Schnell, K. Bise, J. Felsberg, G. Reifenberger, J.C. Tonn, H.A. Kretzschmar, Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer. 121, 2458–2464 (2007)PubMedCrossRef
9.
C. Hartmann, W. Mueller, A. von Deimling, Pathology and molecular genetics of oligodendroglial tumors. J. Mol. Med. 82, 638–655 (2004)PubMedCrossRef
10.
L.R. Henry, H.O. Lee, J.S. Lee, A. Klein-Szanto, P. Watts, E.A. Ross, W.T. Chen, J.D. Cheng, Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 13, 1736–1741 (2007)PubMedCrossRef
11.
H. Huang, Y. Okamoto, H. Yokoo, F.L. Heppner, A. Vital, M. Fevre-Montange, A. Jouvet, Y. Yonekawa, E.N. Lazaridis, P. Kleihues, H. Ohgaki, Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene. 23, 6012–6022 (2004)PubMedCrossRef
12.
A. Idbaih, Y. Marie, G. Pierron, C. Brennetot, K. Hoang-Xuan, M. Kujas, K. Mokhtari, M. Sanson, J. Lejeune, A. Aurias, O. Delattre, J.Y. Delattre, Two types of chromosome 1p losses with opposite significance in gliomas. Ann. Neurol. 58, 483–487 (2005)PubMedCrossRef
13.
Y. Ino, R.A. Betensky, M.C. Zlatescu, H. Sasaki, D.R. Macdonald, A.O. Stemmer-Rachamimov, D.A. Ramsay, J.G. Cairncross, D.N. Louis, Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7, 839–845 (2001)PubMed
14.
M.D. Jenkinson, D.G. du Plessis, T.S. Smith, K.A. Joyce, P.C. Warnke, C. Walker, Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 129, 1884–1891 (2006)PubMedCrossRef
15.
T. Kelly, Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updat. 8, 51–58 (2005)PubMedCrossRef
16.
J.H. Kim, J.H. Shin, I.H. Kim, Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174–1180 (2004)PubMedCrossRef
17.
V.A. Levin, M.S. Edwards, D.C. Wright, M.L. Seager, T.P. Schimberg, J.J. Townsend, C.B. Wilson, Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat. Rep. 64, 237–244 (1980)PubMed
18.
Y. Liang, M. Diehn, N. Watson, A.W. Bollen, K.D. Aldape, M.K. Nicholas, K.R. Lamborn, M.S. Berger, D. Botstein, P.O. Brown, M.A. Israel, Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl Acad. Sci. U.S.A. 102, 5814–5819 (2005)PubMedCrossRef
19.
J.W. Lindsey, Dexamethasone-induced Ras-related protein 1 is a potential regulatory protein in B lymphocytes. Int. Immunol. 19, 583–590 (2007)PubMedCrossRef
20.
K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25, 402–408 (2001)PubMedCrossRef
21.
Z. Lwin, H.K. Gan, W.P. Mason, Low-grade oligodendroglioma: current treatments and future hopes. Expert Rev. Anticancer Ther. 9, 1651–1661 (2009)PubMedCrossRef
22.
D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., J.G. Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277–1280 (1990)PubMed
23.
R. Mehrian Shai, J.K. Reichardt, H. Ya-Hsuan, T.J. Kremen, L.M. Liau, T.F. Cloughesy, P.S. Mischel, S.F. Nelson, Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res. Mol. Brain Res. 136, 99–103 (2005)PubMedCrossRef
24.
P.S. Mischel, R. Shai, T. Shi, S. Horvath, K.V. Lu, G. Choe, D. Seligson, T.J. Kremen, A. Palotie, L.M. Liau, T.F. Cloughesy, S.F. Nelson, Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 22, 2361–2373 (2003)PubMedCrossRef
25.
A. Mukasa, K. Ueki, S. Matsumoto, S. Tsutsumi, R. Nishikawa, T. Fujimaki, A. Asai, T. Kirino, H. Aburatani, Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene. 21, 3961–3968 (2002)PubMedCrossRef
26.
J. Pramana, N. Pimentel, I. Hofland, L.F. Wessels, M.L. van Velthuysen, D. Atsma, C.R. Rasch, M.W. van den Brekel, A.C. Begg, Heterogeneity of gene expression profiles in head and neck cancer. Head Neck. 29, 1083–1089 (2007)PubMedCrossRef
27.
T. Ramirez-Montagut, N.E. Blachere, E.V. Sviderskaya, D.C. Bennett, W.J. Rettig, P. Garin-Chesa, A.N. Houghton, FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 23, 5435–5446 (2004)PubMedCrossRef
28.
G. Reifenberger, D.N. Louis, Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111–126 (2003)PubMed
29.
T. Rikimaru, A. Taketomi, Y. Yamashita, K. Shirabe, T. Hamatsu, M. Shimada, Y. Maehara, Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 72, 69–74 (2007)PubMedCrossRef
30.
N. Sanai, M.S. Berger, Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62, 753–764 (2008). discussion 264–756PubMedCrossRef
31.
B.W. Scheithauer, G.N. Fuller, S.R. VandenBerg, The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol. 18, 307–316 (2008)PubMedCrossRef
32.
R. Shai, T. Shi, T.J. Kremen, S. Horvath, L.M. Liau, T.F. Cloughesy, P.S. Mischel, S.F. Nelson, Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22, 4918–4923 (2003)PubMedCrossRef
33.
J. Stremenova, E. Krepela, V. Mares, J. Trim, V. Dbaly, J. Marek, Z. Vanickova, V. Lisa, C. Yea, A. Sedo, Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int. J. Oncol. 31, 785–792 (2007)PubMed
34.
T. Taira, J. Maeda, T. Onishi, H. Kitaura, S. Yoshida, H. Kato, M. Ikeda, K. Tamai, S.M. Iguchi-Ariga, H. Ariga, AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC. Genes Cells. 3, 549–565 (1998)PubMedCrossRef
35.
B. Tews, J. Felsberg, C. Hartmann, A. Kunitz, M. Hahn, G. Toedt, K. Neben, L. Hummerich, A. von Deimling, G. Reifenberger, P. Lichter, Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int. J. Cancer. 119, 792–800 (2006)PubMedCrossRef
36.
J. Tilgner, M. Herr, C. Ostertag, B. Volk, Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis—influence of clinical factors. Neurosurgery 56, 257–265 (2005). discussion 257–265PubMedCrossRef
37.
V.G. Tusher, R. Tibshirani, G. Chu, Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. U.S.A. 98, 5116–5121 (2001)PubMedCrossRef
38.
G. Vaidyanathan, M.J. Cismowski, G. Wang, T.S. Vincent, K.D. Brown, S.M. Lanier, The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene. 23, 5858–5863 (2004)PubMedCrossRef
39.
M.J. van den Bent, A.F. Carpentier, A.A. Brandes, M. Sanson, M.J. Taphoorn, H.J. Bernsen, M. Frenay, C.C. Tijssen, W. Grisold, L. Sipos, H. Haaxma-Reiche, J.M. Kros, M.C. van Kouwenhoven, C.J. Vecht, A. Allgeier, D. Lacombe, T. Gorlia, Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715–2722 (2006)PubMedCrossRef
40.
M.J. van den Bent, L.H. Looijenga, K. Langenberg, W. Dinjens, W. Graveland, L. Uytdewilligen, P.A. Sillevis Smitt, R.B. Jenkins, J.M. Kros, Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 97, 1276–1284 (2003)PubMedCrossRef
41.
M.J. Van den Bent, M. Reni, G. Gatta, C. Vecht, Oligodendroglioma. Crit. Rev. Oncol. Hematol. 66, 262–272 (2008)PubMedCrossRef
42.
D.A. Vandeputte, D. Troost, S. Leenstra, H. Ijlst-Keizers, M. Ramkema, D.A. Bosch, F. Baas, N.K. Das, E. Aronica, Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 38, 329–338 (2002)PubMedCrossRef
43.
C. Walker, D.G. du Plessis, K.A. Joyce, D. Fildes, A. Gee, B. Haylock, D. Husband, T. Smith, J. Broome, P.C. Warnke, Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol. 57, 855–865 (2005)PubMedCrossRef
44.
C. Walker, D.G. du Plessis, K.A. Joyce, Y. Machell, J. Thomson-Hehir, S.A. Al Haddad, J.C. Broome, P.C. Warnke, Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin. Cancer Res. 9, 4841–4851 (2003)PubMed
45.
C. Walker, B. Haylock, D. Husband, K.A. Joyce, D. Fildes, M.D. Jenkinson, T. Smith, J. Broome, D.G. du Plessis, P.C. Warnke, Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology. 66, 1661–1667 (2006)PubMedCrossRef
46.
M.A. Watson, A. Perry, V. Budhjara, C. Hicks, W.D. Shannon, K.M. Rich, Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 61, 1825–1829 (2001)PubMed
47.
B. Wiesenhofer, G. Stockhammer, H. Kostron, H. Maier, H. Hinterhuber, C. Humpel, Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol. 99, 131–137 (2000)PubMedCrossRef
48.
R. Yamanaka, T. Arao, N. Yajima, N. Tsuchiya, J. Homma, R. Tanaka, M. Sano, A. Oide, M. Sekijima, K. Nishio, Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene. 25, 5994–6002 (2006)PubMedCrossRef
49.
S. Yip, A.J. Iafrate, D.N. Louis, Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J. Neuropathol. Exp. Neurol. 67, 1–15 (2008)PubMedCrossRef
50.
M.Z. Zhang, Y.H. Qiao, J.M. Nesland, Z.H. Suo, Expression of seprase in effusions from patients with epithelial ovarian carcinoma. Chin. Med. J. (Engl) 120, 663–668 (2007)
Metadata
Title
Gene expression in oligodendroglial tumors
Authors
Elisabeth J. Shaw
Brian Haylock
David Husband
Daniel du Plessis
D. Ross Sibson
Peter C. Warnke
Carol Walker
Publication date
01-08-2011
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-011-0036-6

Other articles of this Issue 4/2011

Cellular Oncology 4/2011 Go to the issue

Original Paper

Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment

Original Paper

Dual effects of β3 integrin subunit expression on human pancreatic cancer models

Original Paper

The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival

Original Paper

High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow

Original Paper

Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737

Original Paper

Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits